The baseline NT-proBNP levels in these RA patients (median 100 pg/ml) were higher than one might see in a general population; indeed, median NT-proBNP in the ASCOT trial of patients with hypertension and other CVD risk factors was 89 pg/ml [18]. This evidence concerns the gene NPPB and rheumatoid arthritis.